Effects of dopamine D1 and D2 receptor antagonists on laryngeal neurophysiology in the rat

Journal of Neurophysiology

Volumn 102, Issue 2, 2009, Pages 1193-1205

  Feng, Xin ^a   Henriquez, Victor M ^a   Walters, Judith R ^b   Ludlow, Christy L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ETICLOPRIDE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; SALICYLAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; LARYNX; LARYNX MUSCLE; MALE; MUSCLE EXCITATION; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUPERIOR LARYNGEAL NERVE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROMYOGRAPHY; ELECTROSTIMULATION; LARYNGEAL NERVE; LARYNX DISORDER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTROMYOGRAPHY; LARYNGEAL DISEASES; LARYNGEAL MUSCLES; LARYNGEAL NERVES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TIME FACTORS;

EID: 68149149611     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00121.2009     Document Type: Article

References (53)

1. Agostino R, Bologna M, Dinapoli L, Gregori B, Fabbrini G, Accornero N, Berardelli A. Voluntary, spontaneous, and reflex blinking in Parkinson's disease. Mov Disord 23: 669-675, 2008.
2. Ambalavanar R, Tanaka Y, Selbie WS, Ludlow CL. Neuronal activation in the medulla oblongata during selective elicitation of the laryngeal adductor response. J Neurophysiol 92: 2920-2932, 2004.
3. Bartlett D Jr, Remmers JE, Gautier H. Laryngeal regulation of respiratory airflow. Respir Physiol 18: 194-204, 1973.
4. Basso MA, Strecker RE, Evinger C. Midbrain 6-hydroxydopamine lesions modulate blink reflex excitability. Exp Brain Res 94: 88-96, 1993.
5. Bhabu P, Poletto C, Mann E, Bielamowicz S, Ludlow CL. Thyroarytenoid muscle responses to air pressure stimulation of the laryngeal mucosa in humans. Ann Otol Rhinol Laryngol 112: 834-840, 2003.
6. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203-219, 1991.
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211, 2003.
8. Ciucci MR, Ahrens AM, Ma ST, Kane JR, Windham EB, Woodlee MT, Schallert T. Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats. Behav Neurosci 123: 328-336, 2009.
9. Ciucci MR, Ma ST, Fox C, Kane JR, Ramig LO, Schallert T. Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav Brain Res 182: 284-289, 2007.
10. Civelli O, Bunzow JR, Grandy DK, Zhou QY, Van Tol HH. Molecular biology of the dopamine receptors. Eur J Pharmacol 207: 277-286, 1991.
11. Deng YP, Lei WL, Reiner A. Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling. J Chem Neuroanat 32: 101-116, 2006.
12. Double KL, Crocker AD. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA 92: 1669-1673, 1995.
13. Dromey C, Kumar R, Lang AE, Lozano AM. An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. Mov Disord 15: 1132-1138, 2000.
14. Ebihara S, Saito H, Kanda A, Nakajoh M, Takahashi H, Arai H, Sasaki H. Impaired efficacy of cough in patients with Parkinson disease. Chest 124: 1009-1015, 2003.
15. Elsworth JD, Lawrence MS, Roth RH, Taylor JR, Mailman RB, Nichols DE, Lewis MH, Redmond DE Jr. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther 259: 595-600, 1991.
16. Gallena S, Smith PJ, Zeffiro T, Ludlow CL. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J Speech Lang Hear Res 44: 1284-1299, 2001.
17. Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, Teper Y, Jupp B, Ziebell J, Morganti-Kossmann CM, O'Brien TJ, Nally R, Schutz G, Waddington J, Egan GF, Drago J. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci USA 104: 4182-4187, 2007.
18. Goberman AM. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson disease. Med Sci Monit 11: CR109-CR116, 2005.
19. Hemsley KM, Crocker AD. The effects of an irreversible dopamine receptor antagonist, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), on the regulation of muscle tone in the rat: the role of the substantia nigra. Neurosci Lett 251: 77-80, 1998.
20. Hemsley KM, Crocker AD. Changes in muscle tone are regulated by D1 and D2 dopamine receptors in the ventral striatum and D1 receptors in the substantia nigra. Neuropsychopharmacology 25: 514-526, 2001.
21. Hemsley KM, Farrall EJ, Crocker AD. Dopamine receptors in the subthalamic nucleus are involved in the regulation of muscle tone in the rat. Neurosci Lett 317: 123-126, 2002.
22. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58: S1-S8, 2002.
23. Jobst EE, Melnick ME, Byl NN, Dowling GA, Aminoff MJ. Sensory perception in Parkinson disease. Arch Neurol 54: 450-454, 1997.
24. Jurgens U. A study of the central control of vocalization using the squirrel monkey. Med Eng Phys 24: 473-477, 2002.
25. Jurgens U. The neural control of vocalization in mammals: a review. J Voice 23: 1-10, 2009.
26. Jurgens U, Ehrenreich L. The descending motorcortical pathway to the laryngeal motoneurons in the squirrel monkey. Brain Res 1148: 90-95, 2007.
27. Jutkiewicz EM, Bergman J. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions. J Pharmacol Exp Ther 311: 1008-1015, 2004.
28. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34: 284-295, 2008.
29. Kimura J. Disorder of interneurons in parkinsonism. The orbicularis oculi reflex to paired stimuli. Brain 96: 87-96, 1973.
30. Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 54: 458-462, 2000.
31. Kuna ST, Insalaco G, Woodson GE. Thyroarytenoid muscle activity during wakefulness and sleep in normal adults. J Appl Physiol 65: 1332-1339, 1988.
32. Kuna ST, Smickley JS, Vanoye CR, McMillan TH. Cricothyroid muscle activity during sleep in normal adult humans. J Appl Physiol 76: 2326-2332, 1994.
33. Leanderson R, Meyerson BA, Persson A. Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory function. J Neurol Neurosurg Psychiatry 34: 679-681, 1971.
34. Logemann JA, Fisher HB, Boshes B, Blonsky ER. Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J Speech Hear Disord 43: 47-57, 1978.
35. Lozza A, Pepin JL, Rapisarda G, Moglia A, Delwaide PJ. Functional changes of brainstem reflexes in Parkinson's disease. Conditioning of the blink reflex R2 component by paired and index finger stimulation. J Neural Transm 104: 679-687, 1997.
36. Ludlow CL, Schulz GM, Yamashita T, Deleyiannis FW. Abnormalities in long latency responses to superior laryngeal nerve stimulation in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 104: 928-935, 1995.
37. Luschei ES, Ramig LO, Baker KL, Smith ME. Discharge characteristics of laryngeal single motor units during phonation in young and older adults and in persons with Parkinson disease. J Neurophysiol 81: 2131-2139, 1999.
38. McKelvey D, Hollingshead KW. Small Animal Anesthesia and Analgesia (2nd ed.). St. Louis, MO: Mosby, 2000, p. 49-54.
39. Memo M. Pharmacological and molecular basis for dopamine D-2 receptor diversity. Mol Neurobiol 4: 181-196, 1990.
40. Plowman-Prine EK, Okun MS, Sapienza CM, Shrivastav R, Fernandez HH, Foote KD, Ellis C, Rodriguez AD, Burkhead LM, Rosenbek JC. Perceptual characteristics of parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehabilitation 24: 131-144, 2009.
41. Pollack A. Coactivation of D1 and D2 dopamine receptors: in marriage, a case of his, hers, and theirs. Sci STKE 2004: pe50, 2004.
42. Raffaele R, Emery P, Palmeri A, Ricca G, Perciavalle V. Influences of dopaminergic systems on the blink reflex. Ital J Neurol Sci 9: 351-354, 1988.
43. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson's disease therapy. Ann Neurol 53, Suppl. 3: S3-S15, 2003.
44. Rousseaux M, Krystkowiak P, Kozlowski O, Ozsancak C, Blond S, Destee A. Effects of subthalamic nucleus stimulation on parkinsonian dysarthria and speech intelligibility. J Neurol 251: 327-334, 2004.
45. Schneider JS, Diamond SG, Markham CH. Deficits in orofacial sensorimotor function in Parkinson's disease. Ann Neurol 19: 275-282, 1986.
46. Seeman P, Nam D, Ulpian C, Liu IS, Tallerico T. New dopamine receptor, D2(Longer), with unique TG splice site, in human brain. Brain Res Mol Brain Res 76: 132-141, 2000.
47. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1991.
48. Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Responsiveness of impairments and disabilities in Parkinson's disease. Parkinsonism Relat Disord 12: 314-318, 2006.
49. Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236: 719-722, 1987.
50. Weick BG, Walters JR. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Brain Res 405: 234-246, 1987.
51. Whelan G, Flecknell PA. The assessment of depth of anaesthesia in animals and man. Lab Anim 26: 153-162, 1992.
52. Wolfe VI, Garvin JS, Bacon M, Waldrop W. Speech changes in Parkinson's disease during treatment with L-dopa. J Commun Disord 8: 271-279, 1975.
53. Zarzur AP, Duprat AC, Shinzato G, Eckley CA. Laryngeal electromyography in adults with Parkinson's disease and voice complaints. Laryngoscope 117: 831-834, 2007.